Your browser is no longer supported. Please, upgrade your browser.
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own0.10% Shs Outstand160.66M Perf Week-4.34%
Market Cap3.45B Forward P/E- EPS next Y-0.90 Insider Trans-7.84% Shs Float160.16M Perf Month-1.26%
Income-191.50M PEG- EPS next Q-0.24 Inst Own91.80% Short Float4.13% Perf Quarter17.34%
Sales474.40M P/S7.28 EPS this Y-12.00% Inst Trans0.52% Short Ratio4.07 Perf Half Y-1.30%
Book/sh3.53 P/B6.00 EPS next Y11.80% ROA-25.70% Target Price29.05 Perf Year-59.91%
Cash/sh3.31 P/C6.39 EPS next 5Y25.00% ROE-32.70% 52W Range15.68 - 54.58 Perf YTD-9.25%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-45.80% 52W High-61.19% Beta0.63
Dividend %- Quick Ratio7.10 Sales past 5Y491.50% Gross Margin95.40% 52W Low35.08% ATR1.47
Employees570 Current Ratio7.30 Sales Q/Q9.10% Oper. Margin-40.70% RSI (14)43.53 Volatility6.73% 5.65%
OptionableYes Debt/Eq0.00 EPS Q/Q83.20% Profit Margin-40.40% Rel Volume1.78 Prev Close21.49
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume1.63M Price21.18
Recom2.60 SMA20-8.36% SMA50-3.12% SMA2002.11% Volume2,901,229 Change-1.44%
Jan-05-22Upgrade Citigroup Neutral → Buy $30
Dec-21-21Downgrade Guggenheim Buy → Neutral $28
Nov-01-21Upgrade Guggenheim Neutral → Buy $23
Oct-14-21Downgrade Morgan Stanley Overweight → Equal-Weight $20
Sep-23-21Resumed Needham Hold
Jun-10-21Initiated Berenberg Hold $29
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral $43 → $18
Apr-06-21Downgrade Mizuho Buy → Neutral $37 → $25
Apr-06-21Downgrade Jefferies Buy → Hold $40 → $21
Apr-06-21Downgrade Goldman Buy → Neutral $73 → $25
Apr-06-21Downgrade Canaccord Genuity Buy → Hold $40 → $26
Apr-05-21Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21Downgrade BofA Securities Buy → Neutral
Mar-09-21Reiterated H.C. Wainwright Buy $60 → $43
Mar-09-21Downgrade Stifel Buy → Hold $68 → $27
Mar-09-21Downgrade Raymond James Strong Buy → Outperform $65 → $35
Mar-09-21Downgrade Guggenheim Buy → Neutral
Mar-09-21Downgrade Citigroup Buy → Neutral $66 → $35
Dec-16-20Initiated Mizuho Buy $69
Nov-16-20Upgrade Raymond James Outperform → Strong Buy $65
Jan-13-22 11:13AM  
Jan-11-22 11:56AM  
Jan-10-22 01:20PM  
07:00AM  
Dec-22-21 05:24PM  
09:00AM  
Dec-21-21 04:12PM  
11:29AM  
Dec-20-21 04:05PM  
Dec-14-21 09:00AM  
Dec-11-21 05:38AM  
Dec-08-21 08:35AM  
Dec-07-21 12:29PM  
08:33AM  
07:25AM  
Dec-06-21 05:23PM  
04:05PM  
Dec-01-21 09:00AM  
Nov-26-21 03:58PM  
Nov-16-21 09:00AM  
Nov-09-21 11:08AM  
Nov-08-21 05:25PM  
04:05PM  
Nov-02-21 09:00AM  
Nov-01-21 04:05PM  
Oct-29-21 01:35PM  
Oct-27-21 03:03PM  
01:46PM  
09:00AM  
Oct-25-21 09:44AM  
09:00AM  
Oct-23-21 06:08AM  
Oct-15-21 08:25AM  
Sep-03-21 11:31AM  
Sep-02-21 09:00AM  
Sep-01-21 04:05PM  
Aug-26-21 09:55AM  
Aug-22-21 08:04AM  
Aug-06-21 04:31PM  
01:54PM  
Aug-05-21 04:05PM  
12:53PM  
Aug-04-21 05:25PM  
Aug-03-21 07:30PM  
Jul-28-21 03:03PM  
Jul-21-21 05:05PM  
09:00AM  
Jul-16-21 11:22AM  
Jul-14-21 09:00AM  
Jul-06-21 11:37AM  
Jun-21-21 05:02PM  
03:33PM  
09:45AM  
09:09AM  
05:40AM  
01:00AM  
Jun-20-21 12:20PM  
11:35AM  
11:10AM  
Jun-19-21 04:06PM  
08:26AM  
Jun-18-21 08:20PM  
06:30PM  
02:32PM  
01:05PM  
12:00PM  
10:57AM  
10:00AM  
Jun-17-21 11:41AM  
11:00AM  
10:56AM  
09:36AM  
06:08AM  
01:00AM  
Jun-16-21 10:00PM  
03:20PM  
02:30PM  
02:10PM  
01:10PM  
11:40AM  
11:15AM  
11:00AM  
10:55AM  
Jun-15-21 02:15PM  
12:43PM  
12:05PM  
12:00PM  
11:45AM  
11:15AM  
10:54AM  
10:30AM  
10:00AM  
Jun-14-21 09:00PM  
07:23PM  
06:28PM  
05:00PM  
02:30PM  
01:00PM  
11:30AM  
11:00AM  
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAVIS STEPHENCEOJan 06Sale23.053,71885,70058,716Jan 10 06:22 PM
Stankovic Srdjan R.PresidentJan 06Sale23.051,93744,64845,019Jan 10 06:23 PM
KIM AUSTIN D.EVP & General CounselJan 06Sale23.0557413,23113,200Jan 10 06:24 PM
Teehan BrendanEVP, COO, Head of CommercialJan 06Sale23.0553812,4011,788Jan 10 06:25 PM
Stankovic Srdjan R.PresidentNov 22Sale19.012,80353,28541,512Nov 23 06:00 PM
Stankovic Srdjan R.PresidentOct 18Sale17.411,33823,29538,065Oct 19 05:31 PM
DAVIS STEPHENCEOOct 18Sale17.412,96351,58652,906Oct 19 05:30 PM
Ridloff ElenaEVP and CFOApr 30Sale20.331,03220,98110,553Apr 30 06:55 PM
KIM AUSTIN D.EVP & General CounselApr 30Sale20.331,05421,42811,371Apr 30 06:54 PM
Stankovic Srdjan R.PresidentApr 30Sale20.334,23085,99636,434Apr 30 06:53 PM
DAVIS STEPHENCEOApr 30Sale20.337,850159,59049,312Apr 30 06:52 PM
KIM AUSTIN D.EVP & General CounselFeb 04Sale50.612,107106,6359,911Feb 08 09:00 PM
Stankovic Srdjan R.PresidentFeb 04Sale50.618,429426,59231,049Feb 08 09:00 PM
DAVIS STEPHENCEOFeb 04Sale50.6114,195718,40928,900Feb 08 09:00 PM
Ridloff ElenaEVP and CFOFeb 04Sale50.612,051103,8018,340Feb 08 09:00 PM